Literature DB >> 34244807

Implementation of quality improvement coaching versus physician communication training for improving human papillomavirus vaccination in primary care: a randomized implementation trial.

Brigid K Grabert1,2, Rachel Kurtzman1,2, Jennifer Heisler-MacKinnon2, Jennifer Leeman1,3, Adam Bjork4,5, Maddy Kameny6, Amy Liu7, Karen Todd8, Susan Alton Dailey2, Kevin Smith9, Noel T Brewer1,2, Melissa B Gilkey1,2.   

Abstract

Many US health departments (HDs) conduct in-person quality improvement (QI) coaching to help primary care clinics improve their HPV vaccine delivery systems and communication. Some HDs additionally conduct remote communication training to help vaccine prescribers recommend HPV vaccination more effectively. Our aim was to compare QI coaching and communication training on key implementation outcomes. In a cluster randomized trial, we offered 855 primary care clinics: 1) QI coaching; 2) communication training; or 3) both interventions combined. In each trial arm, we assessed adoption (proportion of clinics receiving the intervention), contacts per clinic (mean number of contacts needed for one clinic to adopt intervention), reach (median number of participants per clinic), and delivery cost (mean cost per clinic) from the HD perspective. More clinics adopted QI coaching than communication training or the combined intervention (63% vs 16% and 12%, both p < .05). QI coaching required fewer contacts per clinic than communication training or the combined intervention (mean = 4.7 vs 29.0 and 40.4, both p < .05). Communication training and the combined intervention reached more total staff per clinic than QI coaching (median= 5 and 5 vs 2, both p < .05), including more prescribers (2 and 2 vs 0, both p < .05). QI coaching cost $439 per adopting clinic on average, including follow up ($129/clinic), preparation ($73/clinic), and travel ($69/clinic). Communication training cost $1,287 per adopting clinic, with most cost incurred from recruitment ($653/clinic). QI coaching was lower cost and had higher adoption, but communication training achieved higher reach, including to influential vaccine prescribers. © Society of Behavioral Medicine 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cancer prevention; Human papillomavirus vaccine; IQIP; Implementation science; Physician communication; Quality improvement

Mesh:

Substances:

Year:  2022        PMID: 34244807      PMCID: PMC8919808          DOI: 10.1093/tbm/ibab071

Source DB:  PubMed          Journal:  Transl Behav Med        ISSN: 1613-9860            Impact factor:   3.626


  39 in total

1.  Identifying Strategies to Reduce Missed Opportunities for HPV Vaccination in Primary Care: A Qualitative Study of Positive Deviants.

Authors:  Cynthia M Rand; Cathleen Concannon; Rachel Wallace-Brodeur; Wendy Davis; Christina S Albertin; Sharon G Humiston; Peter G Szilagyi
Journal:  Clin Pediatr (Phila)       Date:  2020-06-29       Impact factor: 1.168

2.  Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices.

Authors:  Elissa Meites; Allison Kempe; Lauri E Markowitz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-12-16       Impact factor: 17.586

3.  Implementation Challenges and Opportunities Related to HPV Vaccination Quality Improvement in Primary Care Clinics in a Rural State.

Authors:  Natoshia M Askelson; Grace Ryan; Laura Seegmiller; Felicia Pieper; Bethany Kintigh; Donald Callaghan
Journal:  J Community Health       Date:  2019-08

4.  A quality improvement education initiative to increase adolescent human papillomavirus (HPV) vaccine completion rates.

Authors:  Cynthia A Bonville; Joseph B Domachowske; Manika Suryadevara
Journal:  Hum Vaccin Immunother       Date:  2019-06-26       Impact factor: 3.452

5.  Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda.

Authors:  Enola Proctor; Hiie Silmere; Ramesh Raghavan; Peter Hovmand; Greg Aarons; Alicia Bunger; Richard Griffey; Melissa Hensley
Journal:  Adm Policy Ment Health       Date:  2011-03

Review 6.  Practice- and Community-Based Interventions to Increase Human Papillomavirus Vaccine Coverage: A Systematic Review.

Authors:  Linda M Niccolai; Caitlin E Hansen
Journal:  JAMA Pediatr       Date:  2015-07       Impact factor: 16.193

7.  Provider communication and HPV vaccination: The impact of recommendation quality.

Authors:  Melissa B Gilkey; William A Calo; Jennifer L Moss; Parth D Shah; Macary W Marciniak; Noel T Brewer
Journal:  Vaccine       Date:  2016-01-24       Impact factor: 3.641

8.  Improving HPV Vaccination Rates: A Stepped-Wedge Randomized Trial.

Authors:  Rebecca B Perkins; Aaron Legler; Emily Jansen; Judith Bernstein; Natalie Pierre-Joseph; Terresa J Eun; Dea L Biancarelli; Thomas J Schuch; Karin Leschly; Anny T H R Fenton; William G Adams; Jack A Clark; Mari-Lynn Drainoni; Amresh Hanchate
Journal:  Pediatrics       Date:  2020-06-15       Impact factor: 7.124

9.  Why is announcement training more effective than conversation training for introducing HPV vaccination? A theory-based investigation.

Authors:  Teri L Malo; Megan E Hall; Noel T Brewer; Christine R Lathren; Melissa B Gilkey
Journal:  Implement Sci       Date:  2018-04-19       Impact factor: 7.327

View more
  2 in total

1.  Partnering with healthcare systems to improve HPV vaccination:The perspective of immunization program managers.

Authors:  Brigid K Grabert; Jennifer Heisler-MacKinnon; Rachel Kurtzman; Adam Bjork; Katelyn Wells; Noel T Brewer; Melissa B Gilkey
Journal:  Hum Vaccin Immunother       Date:  2021-10-29       Impact factor: 3.452

2.  Coaching and Communication Training for HPV Vaccination: A Cluster Randomized Trial.

Authors:  Melissa B Gilkey; Brigid K Grabert; Jennifer Heisler-MacKinnon; Adam Bjork; Marcella H Boynton; KyungSu Kim; Susan Alton Dailey; Amy Liu; Karen G Todd; Stephanie L Schauer; Danielle Sill; Scott Coley; Noel T Brewer
Journal:  Pediatrics       Date:  2022-08-01       Impact factor: 9.703

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.